Literature DB >> 23216236

The differences in CXCR4 protein expression are significant for the five molecular subtypes of breast cancer.

Ming Zhang1, Hai-Xia Liu, Xiao-Dan Teng, Hong-Bin Wang, Jing Cui, Shu-Sheng Jia, Xin-Yue Gu, Zhi-Gao Li.   

Abstract

The aim was to investigate the expression of the CXCR4 protein in five molecular subtypes of breast cancer. The authors randomly selected the breast cancer paraffin-embedded specimens of the Affiliated Third Hospital of Harbin Medical University between 2007 and 2009. Details are as follows: basal-like subtype-ER (-), PR (-), C-erbB-2 (-), CK5/6 (+), n = 36; normal breast subtype-ER (-), PR (-), C-erbB-2 (-), CK5/6(-), n = 40; luminal A subtype-ER/PR (+), C-erbB-2 (-), n = 38; luminal B subtype-ER/PR (+), C-erbB-2 (+), n = 60; C-erbB-2 (+) subtype-ER (-), PR (-), C-erbB-2 (+), n = 58. Using the immunohistochemistry method, the authors detected the expression of the CXCR4 protein in the five subtypes. The CXCR4 protein expression in the basal-like subtype was the highest, and that in the luminal A subtype was the lowest. In terms of five molecular subtypes of breast cancer, the differences in CXCR4 protein expression were significant (p < .001). In terms of C-erbB-2 expression, tumor stage, and lymph node metastasis of breast cancer, the differences in CXCR4 protein expression were significant (p < .01).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23216236     DOI: 10.3109/01913123.2012.728687

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  14 in total

1.  CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer.

Authors:  Alda Losi Guembarovski; Roberta Losi Guembarovski; Bruna Karina Banin Hirata; Glauco Akelinghton Freire Vitiello; Karen Mayumi Suzuki; Mayara Tiemi Enokida; Maria Angelica Ehara Watanabe; Edna Maria Vissoci Reiche
Journal:  Mol Biol Rep       Date:  2018-06-20       Impact factor: 2.316

2.  CXCL12 Retargeting of an Oncolytic Adenovirus Vector to the Chemokine CXCR4 and CXCR7 Receptors in Breast Cancer.

Authors:  Samia M O'Bryan; J Michael Mathis
Journal:  J Cancer Ther       Date:  2021-06

3.  Heightened CXCR4 and CXCL12 expression in NF1-associated neurofibromas.

Authors:  Beren Karaosmanoglu; Çetin Y Kocaefe; Figen Söylemezoğlu; Banu Anlar; Ali Varan; İbrahim Vargel; Sükriye Ayter
Journal:  Childs Nerv Syst       Date:  2018-02-17       Impact factor: 1.475

4.  CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.

Authors:  Jingyu Xiang; Michelle A Hurchla; Francesca Fontana; Xinming Su; Sarah R Amend; Alison K Esser; Garry J Douglas; Chidananda Mudalagiriyappa; Kathryn E Luker; Timothy Pluard; Foluso O Ademuyiwa; Barbara Romagnoli; Gérald Tuffin; Eric Chevalier; Gary D Luker; Michael Bauer; Johann Zimmermann; Rebecca L Aft; Klaus Dembowsky; Katherine N Weilbaecher
Journal:  Mol Cancer Ther       Date:  2015-08-12       Impact factor: 6.261

Review 5.  Immunohistochemical expression of CXCR4 on breast cancer and its clinical significance.

Authors:  Marina Okuyama Kishima; Carlos Eduardo Coral de Oliveira; Bruna Karina Banin-Hirata; Roberta Losi-Guembarovski; Karen Brajão de Oliveira; Marla Karine Amarante; Maria Angelica Ehara Watanabe
Journal:  Anal Cell Pathol (Amst)       Date:  2015-06-16       Impact factor: 2.916

6.  Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes.

Authors:  Cláudia S Marques; Maria Soares; Ana Santos; Jorge Correia; Fernando Ferreira
Journal:  Oncotarget       Date:  2017-11-11

Review 7.  AlphaB-crystallin and breast cancer: role and possible therapeutic strategies.

Authors:  Daniela Caporossi; Attilio Parisi; Cristina Fantini; Elisa Grazioli; Claudia Cerulli; Ivan Dimauro
Journal:  Cell Stress Chaperones       Date:  2020-10-28       Impact factor: 3.667

8.  The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo.

Authors:  Xiaoyang Ling; Erika Spaeth; Ye Chen; Yuexi Shi; Weiguo Zhang; Wendy Schober; Numsen Hail; Marina Konopleva; Michael Andreeff
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

Review 9.  Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis.

Authors:  Zhigang Zhang; Chao Ni; Wuzhen Chen; Ping Wu; Zhen Wang; Junhua Yin; Jian Huang; Fuming Qiu
Journal:  BMC Cancer       Date:  2014-01-29       Impact factor: 4.430

10.  Extracts from Curcuma zedoaria Inhibit Proliferation of Human Breast Cancer Cell MDA-MB-231 In Vitro.

Authors:  Xiu-Fei Gao; Qing-Lin Li; Hai-Long Li; Hong-Yan Zhang; Jian-Ying Su; Bei Wang; Pei Liu; Ai-Qin Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-05       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.